Use of GLP-1 compound for treatment of critically ill patients
a technology of glp-1 and compound, which is applied in the direction of biocide, plant growth regulator, animal/human protein, etc., can solve the problems of difficulty in rehabilitation, and inability to detect clinical signs, so as to reduce the incidence of critical illness, prevent or reduce the likelihood of a patient suffering, and prolong the time free of critical illness
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Examples
example 1
Materials and Methods
[0153] In a randomized, double-blind, placebo-controlled, crossover study the effect of NN2211 on beta cell sensitivity to glucose was tested in 10 subjects with type 2 diabetes following a single dose of NN2211 (7.5 μg / kg) or placebo. Using a graded glucose infusion protocol with plasma glucose levels matched over the range of 5 to 12 mmol / L beta cell sensitivity was assessed. Insulin secretion rates (ISR) were estimated by deconvolution of circulating C-peptide concentrations. Findings were compared to responses of 10 healthy, non-diabetic volunteers to the same glucose infusion protocol.
Results
[0154] Compared to placebo, a single dose of NN2211 increased insulin and C-peptide levels, increased ISR area under the curve (AUC) (1130±150 vs. 668±106 pmol / kg; p<0.001), and increased slope of ISR vs. plasma glucose (1.26±0.36 vs. 0.54±0.18 pmol*L / (min*mmol*kg); p<0.014), to values similar to nondiabetic controls who did not receive the drug (ISR AUC 1206±99; s...
example 2
Material and Methods
[0156] In a prospective, 12 week, randomised, double-blind, dose-response, placebo controlled and open label glimepiride study in subjects with type 2 diabetes, the glucose lowering effect of NN2211 was tested with the primary endpoint being the effect on HbA1c after 12 weeks treatment (a recognised measure of overall glycaemic control).
[0157] Altogether 193 patients were equally randomised to receive one of 5 dose levels of NN2211 (0.045, 0.225, 0.45, 0.60, or 0.75 mg), placebo (s.c. injection), or glimepiride (p.o.) all given once daily. Placebo and NN2211 was double-blind, whereas glimepiride was open-label. The dose of glimepiride was adjusted during the first 4 weeks based on glycaemic control with a treatment target of fasting serum glucose<7 mM, with a dose not exceeding 4 mg / day.
Results
[0158] For the primary endpoint of the study HbA1c decreased in all NNC 90-1170 treatment groups, except the one at the lowest dosage. In comparison to the placebo gr...
example 3
[0161] Serves as an example of a study that could determine the effect of NN2211 in critically ill patients in comparison to intensive insulin treatment.
Methods
Study Population
[0162] All mechanically ventilated, adult (age>18y) patients.
Study Design and Treatment protocols
[0163] At ICU admission, and following informed consent, patients are randomized to either strict control of glycemia below 6.1 mmol / L (110 mg / dL) with continuously infused insulin, the ‘intensive insulin schedule’ (IIS), or using NN2211 given once daily (1-5 mg).
Baseline Assessment and Data Collection
[0164] At baseline, demographic, diagnostic and therapeutic information as well as information necessary to determine severity of illness and utilization of ICU resources are obtained from each patient. These include APACHE-II (Acute Physiology and Chronic Health Evaluation) score with higher values indicating more severe illness and simplified Therapeutic Intervention Scoring System (TISS-28) with higher v...
PUM
| Property | Measurement | Unit |
|---|---|---|
| pH | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
| time | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More